← Back to Clinical Trials
Recruiting NCT04820764

NCT04820764 EFS of the CardioMech MVRS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04820764
Status Recruiting
Phase
Sponsor CardioMech AS
Condition Mitral Regurgitation
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2021-07-27
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
CardioMech MVRS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25 participants in total. It began in 2021-07-27 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Safety and performance evaluation of the CardioMech Mitral Valve Repair System (MVRS) in patients with degenerative mitral valve regurgitation.

Eligibility Criteria

Inclusion Criteria: * Eighteen (18) years of age or greater * Moderate to severe (≥3+) or severe (≥4+) mitral valve regurgitation (per American Society of Echocardiography (ASE) guidelines) due to mitral valve prolapse or flail * Intermediate or high surgical risk for mitral valve repair Exclusion Criteria: * History of rheumatic heart disease * History of prior endocarditis * History of prior repair or replacement of the mitral valve, or annuloplasty * Severely calcified mitral leaflet or has evidence of calcification in the grasping area of the leaflets that would prevent leaflet anchor positioning and deployment * Complex mechanism of MR (leaflet perforation, severe leaflet calcifications, commissural extension, commissural prolapse, multiple flail or prolapsing segments, cleft) present on required imaging

Contact & Investigator

Central Contact

Jennifer Ruether

✉ jennifer.ruether@cardiomech.com

📞 651-248-4440

Principal Investigator

Mathew Williams, MD

PRINCIPAL INVESTIGATOR

NYU Langone

Frequently Asked Questions

Who can join the NCT04820764 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mitral Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04820764 currently recruiting?

Yes, NCT04820764 is actively recruiting participants. Contact the research team at jennifer.ruether@cardiomech.com for enrollment information.

Where is the NCT04820764 trial being conducted?

This trial is being conducted at Thousand Oaks, United States, Evanston, United States, Wichita, United States, Rochester, United States and 8 additional locations.

Who is sponsoring the NCT04820764 clinical trial?

NCT04820764 is sponsored by CardioMech AS. The principal investigator is Mathew Williams, MD at NYU Langone. The trial plans to enroll 25 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology